Mack Mitchell is a Gastroenterology physician affiliated with The University of Texas Southwestern Medical Center. OpenAlex indexes 146 publications with 4,612 citations (h-index 36); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Ut Southwestern Medical Ctr
5323 Harry Hines Blvd
Dallas, TX 753909030
Telephone
214-648-5036Registry record last updated 4 Oct 2011.
Clinical trials
- Novel Therapies in Moderately Severe Acute Alcoholic Hepatitis
Sponsor: University of Texas Southwestern Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year20252 payments
- Ardelyx, Inc.Program year20253 payments
- ABBVIE INC.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
63.9%Proton pump inhibitor33.7%Omeprazole46%Pantoprazole Sodium44%Esomeprazole Magnesium10%Part D<11 patientsGuanylate Cyclase-C Agonist7.3%Linzess100%Part D<11 patients+ 5 more classes in this area
Cardiovascular
19.9%Bile Acid Sequestrant17%Colestipol Hcl100%Part D≥20 patientsAldosterone antagonist (MRA)3%Spironolactone100%Part D<11 patientsCancer & immunology
6.2%Kinase inhibitor3.2%Everolimus100%Part D<11 patientsCalcineurin inhibitor3%Cyclosporine Modified100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2018–2026 per NIH RePORTER. The latest:
- Integrated therapies for alcohol use and ALD (ITAALD) Network – UTSW Clinical Center
Ut Southwestern Medical Center
FY2026$360,800U01AA026975 - Integrated therapies for alcohol use and ALD (ITAALD) Network – UTSW Clinical Center
Ut Southwestern Medical Center
FY2025$360,800U01AA026975 - Integrated therapies for alcohol use and ALD (ITAALD) Network – UTSW Clinical Center
Ut Southwestern Medical Center
FY2024$360,800U01AA026975
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Randomized trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis
Journal of Hepatology
2024 - Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement
Nature Reviews Gastroenterology & Hepatology
2024 - The Beneficial Effects of Lactobacillus GG Therapy on Liver and Drinking Assessments in Patients with Moderate Alcohol-Associated Hepatitis
The American Journal of Gastroenterology
2023 - Safety, Pharmacokinetics, and Efficacy Signals of Larsucosterol (DUR-928) in Alcohol-Associated Hepatitis
The American Journal of Gastroenterology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Toto, MD
The University of Texas Southwestern Medical Center
Margaret Pearle, MD, PhD
The University of Texas Southwestern Medical Center
George Buchanan, MD
The University of Texas Southwestern Medical Center
Vitaly Margulis, MD
The University of Texas Southwestern Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”